Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

BACKGROUND: Management of type 2 diabetes with metformin often does not provide adequate glycemic control, thereby necessitating add-on treatment. In a 24-week clinical trial, dapagliflozin, an investigational sodium glucose cotransporter 2 inhibitor, improved glycemic control in patients inadequate...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bailey, Clifford J, Gross, Jorge L, Hennicken, Delphine, Iqbal, Nayyar, Mansfield, Traci A, List, James F
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2013
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3606470/
https://ncbi.nlm.nih.gov/pubmed/23425012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1741-7015-11-43
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia